The American Cancer Society projects 5,800 new cancer diagnoses each day, adding pressure to cancer and infusion centers that already care for an estimated 650,000 to 1 million U.S. patients annually. According to LeanTaaS’ State of Cancer Centers in 2026…
Personalized cancer care — where cancer therapies are tailored to the genomic makeup of a patient and their tumor — is no longer a futuristic concept. It’s now a reality. Precision oncology has moved from the research setting into routine clinical…
Precision oncology has long been discussed as the future of cancer care, initially focused on advanced disease management and treatment selection. Today, Molecular Residual Disease (MRD) and Multi-Cancer Early Detection (MCED) are expanding that vision beyond late-stage care and into…
Every 30 seconds, someone in the U.S. hears the words: “You have cancer” – a moment that changes life in an instant. Yet, too often, the greatest struggle isn’t always the disease itself, but the maze of barriers that follow.…
BeOne Medicines is a global oncology company discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of novel therapeutics through its internal capabilities and…